Leukaemia - acute myeloid leukaemia

The PBS subsidises midostaurin for patients with acute myeloid leukaemia (AML).

You’ll get an immediate assessment when you request PBS authorities online.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with midostaurin under the National Health Act 1953, section 100 for patients with AML.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing midostaurin.

Section 100 arrangements

Midostaurin

This item is only PBS-subsidised for non-admitted patients, day admitted patients or patients on discharge who are attending:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

This item isn’t PBS-subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.

Authority applications

Applying for induction and consolidation treatment

Applications for induction and consolidation authority approval to prescribe PBS-subsidised midostaurin to treat AML can be made either:

Applying for initial maintenance treatment

Applications for initial maintenance authority approval to prescribe PBS-subsidised midostaurin to treat AML can be made either in:

All written applications must include the completed:

Applying for continuing maintenance treatment

Applications for continuing maintenance authority approval to prescribe PBS-subsidised midostaurin to treat AML can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 July 2022